Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00432835 · ClinicalTrials.gov registry record · Phase 3
Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis
A Phase 3 study, sponsored by University of Mississippi Medical Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 58
- Enrollment target
NCT00432835: Completed Phase 3 study, sponsored by University of Mississippi Medical Center.
NCT00432835 is a Phase 3 study that has completed, run by University of Mississippi Medical Center. The registered enrollment target is 58 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00432835, a Phase 3 study, has completed, sponsored by University of Mississippi Medical Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 58 participants
- Enrollment target
Study Summary
The purpose of this research is to determine if temporary gastric electrical stimulation will help improve symptoms of gastroparesis (abnormal stomach emptying). We hypothesize that when the device is ON, Gastrointestinal symptoms will decrease by at least 50% from baseline.
Primary Outcome
Likert Scale 0-4 (low-high) using a patient reported outcomes tool
Interventions
- DEVICE Gastric Electrical Stimulator, Enterra, Medtronics, Inc.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2005-08 |
| Est. Completion | 2007-11 |
| Phase | Phase 3 |
What the finished NCT00432835 record still lists
NCT00432835 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which Gastric Electrical Stimulator, Enterra, Medtronics, Inc. is the first listed.
NCT00432835 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00432835 about?
NCT00432835 is a clinical study titled "Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis". The purpose of this research is to determine if temporary gastric electrical stimulation will help improve symptoms of gastroparesis (abnormal stomach emptying). We hypothesize that when the device is ON, Gastrointestinal symptoms will decrease by at least 50% from baseline.
What is the current status of trial NCT00432835?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 58 participants. The study started on 2005-08. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00432835?
The interventions under investigation include: Gastric Electrical Stimulator, Enterra, Medtronics, Inc. (DEVICE).
Who is sponsoring clinical trial NCT00432835?
This trial is sponsored by University of Mississippi Medical Center, which has 96 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00432835's enrollment target sits among peer trials
58 1825th of 2000 higher than 174 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia